Advanced stage of Parkinson disease (PD) is a difficult condition to treat, especially after several years of dopaminergic drugs. Recent development of neurosurgical techniques using deep brain stimulation leads has shown good behavioral results in these advanced PD patients. However, the placement of a stimulation lead in the subthalamic nucleus is a complex, invasive, and long surgical procedure. Such intervention requires sophisticated technical environment, including stereotactic MRI exam, associated with per-operative electrophysiological exploration of deep brain structures. This surgical treatment can therefore be indicated only for a few selected patients, and can not be offered to a large proportion of patients among the potential candidates (estimation of 5000 patients in France). Thus, there is a need to develop therapeutic alternatives that would be technically and practically more convenient, less invasive, and that could be offered to a larger number of patients. Several clinical studies, including one led by our group, have already demonstrated that transcranial magnetic cortical stimulation could improve bradykinesia and shorten motor reaction time in patients with Parkinson disease. The clinical benefit was however moderate, and transient, probably because the stimulating sessions were too short in duration.

A prolonged effect could be obtained with a continuous cortical stimulation. Such a cortical stimulation have already been developed with good clinical tolerance in our hospital since 1991 for chronic neuropathic pain syndromes. In a non-human primate model of late stage Parkinson disease, we have recently demonstrated that prolonged primary motor cortex stimulation significantly improved both akinesia and bradykinesia.

The primary objective of this pilot study will be to evaluate tolerance and efficacy of chronic stimulation of primary motor cortex in 10 patients suffering from advanced stage Parkinson disease, despite the optimisation of dopaminergic treatment. The expected benefit for the patient will be gait improvement, increase movement velocities, and finally a better quality of life associated with reduction in dopaminergic medication and low per-operative morbidity risk

Inclusion Criteria:

• Age between 18 and 70 years
• Idiopathic Parkinson disease, for at least 5 years of evolution
• Asymetric akineto-rigid form, with symptoms predominant in the right side of the body (stimulator will be implanted at the left side).
• Functional impairment score in Off stage (no drug treatment) of 3-4 according to the Hoehn & Yahr scale (see appendix 1)
• UPDRS III score > 40 in Off drug stage (see appendix X).
• UPDRS III score with L-Dopa treatment improved by at least 50% compared to UPDRS III score in off-drug stage

Exclusion Criteria:

• Age superior to 70 years
• Adult patients under guardianship
• Previous neurosurgical operation (s)
• Previous partial or generalised seizures
• MMS score  24 or Mattis score < 130 or MADRS depression score > 20.
• Presence of signal abnormalities on T1- and T2- MRI sequences
• Abnormalities in general exam or biological constants (hemogram, ionogram, hepatic or kidney dysfunction) with a higher surgical risk